NAMS

AI MemoPost-earnings T+1

NewAmsterdam

As of 2026-11-04/Post-earnings T+1/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-11-04 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

RUBENS Phase 3 topline data • 2026-12-31

Base target: $19 / p=0% prob

Biggest risk

Third-quarter revenue was primarily a regulatory-milestone recognition rather than demonstrated recurring commercial demand. R&D expense increased year over year, while pivotal readouts and partner launch execution remain uncertain. [#8-K-2026-11-04]

Invalidation

Break below $10 or thesis failure.

What would change my mind?

European approval, a planned Menarini launch and $643.1 million of September-end cash support continued development. Favorable RUBENS and PREVAIL results could expand the opportunity, but neither outcome is established. [#8-K-2026-11-04]

Research note

Recommendation

—

Confidence

medium

As of

2026-11-04

Base target

$19

p=0%

Bull target

$29

p=0%

Bear target

$10

p=0%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Third-quarter results: milestone revenue, higher R&D spend
European approval, a planned Menarini launch and $643.1 million of September-end cash support continued development.
Favorable RUBENS and PREVAIL results could expand the opportunity, but neither outcome is established.

BearKey bullets

Cash and marketable securities declined from $728.9 million at December 31, 2025 to $643.1 million at September 30, 2026, while quarterly R&D expense increased year over year.
[#8-K-2026-11-04]
Menarini's planned launches may be delayed or generate slower-than-expected royalties; milestone revenue should not be extrapolated as recurring sales.

WatchKey bullets

RUBENS Phase 3 topline data

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Post-earnings T+1

Base case: $19 (p=0%)

Target spread vs base: +53% / -47%

Scenario probabilities

Bull Target: $29 (p=0%)Base Target: $19 (p=0%)Bear Target: $10 (p=0%)

Commentary

The queue labels this a November 3 T+1 follow-up, but the company filed and released third-quarter results on November 4. The $19.90 packet anchor is dated November 3, so it cannot establish a post-release price reaction. Initial analyst target or estimate revisions were not verified; missing reaction data is not positive evidence. Social coverage was unavailable. The negative deterministic directional prior warrants monitoring despite the confirmed European approval and cash balance.

As of 2026-11-04 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Third-quarter results: milestone revenue, higher R&D spend

Scenarios

Bull Target (Scenario probability)

$29 / p=0% prob

Base Target (Scenario probability)

$19 / p=0% prob

Bear Target (Scenario probability)

$10 / p=0% prob

Analysis 2026-11-04 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-12-31
RUBENS Phase 3 topline data
Management expects topline RUBENS data around year-end 2026. The trial evaluates obicetrapib alone or with ezetimibe in patients with type 2 diabetes or metabolic syndrome who need further LDL-C lowering; the outcome remains uncertain. [#8-K-2026-11-04]
Prob 70.00% • Move 12.00% • Priced-in 35.00%
EVENT2026-12-31
Menarini's planned European launch
Following European Commission approval of Ubeslo and Evlarco, partner Menarini plans a German launch by year-end 2026 and a UK launch in 2027. NewAmsterdam is entitled to tiered royalties on Menarini-territory net sales, but launch timing and uptake are unproven. [#8-K-2026-11-04]
Prob 65.00% • Move 5.00% • Priced-in 50.00%
EVENT2027-03-31
PREVAIL cardiovascular-outcomes interim result
Management plans a PREVAIL interim analysis in fourth-quarter 2026, with its result expected in first-quarter 2027. A cardiovascular-outcomes result could materially change the obicetrapib thesis in either direction. [#8-K-2026-11-04]
Prob 65.00% • Move 20.00% • Priced-in 30.00%

Short-term Catalysts

Next few weeks

Third-quarter results: milestone revenue, higher R&D spend
2026-11-04
The November 4 company earnings release furnished with its 8-K reports $19.2 million of quarterly revenue, largely from Menarini regulatory milestones, versus $0.3 million a year earlier. R&D expense rose to $39.4 million from $31.0 million; cash and marketable securities were $643.1 million at September 30. The milestone-driven revenue is not evidence of recurring product sales. [#8-K-2026-11-04]
Prob 100% • Move 0% • Priced-in 0%

Long-term Catalysts

Months to a year

No long-term catalysts

Risks

Cash and marketable securities declined from $728.9 million at December 31, 2025 to $643.1 million at September 30, 2026, while quarterly R&D expense increased year over year. [#8-K-2026-11-04]
Menarini's planned launches may be delayed or generate slower-than-expected royalties; milestone revenue should not be extrapolated as recurring sales. [#8-K-2026-11-04]
No verified post-print analyst revisions or regular-session earnings reaction were available at this early follow-up.
PREVAIL interim and RUBENS topline results may disappoint, be delayed or prove insufficient for further regulatory or commercial progress. [#8-K-2026-11-04]

Peers

Symbol	Summary
AMGN	Large, established biopharma comparator, not a size-matched development-stage valuation peer.
BHVN	Similar-market-cap development-stage biopharma comparator, but not a direct obicetrapib or LDL-C peer.
CLDX	Similar-market-cap clinical-stage biotech comparator; differing programs limit valuation read-through.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-11-04

Loading AI feed…

Symbol

Summary

AMGN

Large, established biopharma comparator, not a size-matched development-stage valuation peer.

BHVN

Similar-market-cap development-stage biopharma comparator, but not a direct obicetrapib or LDL-C peer.

CLDX

Similar-market-cap clinical-stage biotech comparator; differing programs limit valuation read-through.